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Amyotrophic lateral sclerosis (ALS) is characterized by predominant vulnerability and central degeneration of both corticospinal/
corticobulbarmotorneurons(CSMN;“uppermotorneurons”)incerebralcortex,andspinal/bulbarmotorneurons(SMN;“lowermotor
neurons”) in spinal cord and brainstem. Increasing evidence indicates broader cerebral cortex pathology in cognitive, sensory, and
association systems in select cases. It remains unclear whether widely accepted transgenic ALS models, in particular hSOD1
G93A mice,
undergo degeneration of CSMN and molecularly/developmentally closely related populations of nonmotor projection neurons [e.g.,
othersubcerebralprojectionneurons(SCPN)],andwhetherpotentialCSMN/SCPNdegenerationisspecificandearly.Thisrelativelackof
knowledge regarding upper motor neuron pathology in these ALS model mice has hindered both molecular-pathophysiologic under-
standingofALSandtheirusetowardpotentialCSMNtherapeuticapproaches.Here,usingacombinationofanatomic,cellular,transgenic
labeling,andnewlyavailableneuronalsubtype-specificmolecularanalyses,weidentifythatCSMNandrelatednonmotorSCPNspecifi-
cally and progressively degenerate in hSOD1
G93A mice. Degeneration starts quite early and presymptomatically, by postnatal day 30.
Otherneocorticallayers,corticalinterneurons,andotherprojectionneuronpopulations,evenwithinlayerV,arenotsimilarlyaffected.
Nonneuronalpathologyinneocortex(activatedastrogliaandmicroglia)isconsistentwithfindingsinhumanALScortexandinaffected
mouse and human spinal cord. These results indicate previously unknown neuron type-specific vulnerability of CSMN/sensory and
association SCPN, and identify that characteristic dual CSMN and SMN degeneration is conserved in hSOD1
G93A mice. These results
provideafoundationfordetailedinvestigationofCSMN/SCPNvulnerabilityandtowardpotentialCSMNtherapeuticsinALS.
Introduction
Independent,butpresumedtobemechanisticallyrelated,degen-
erationofboth“upper”[corticospinal/corticobulbarmotorneu-
rons (CSMN)] and “lower” [spinal/bulbar motor neurons
(SMN)] components of motor neuron circuitry (Lefebvre et al.,
1998; Gavrilina et al., 2008) distinguishes amyotrophic lateral
sclerosis (ALS) from disorders characterized by marked vulnera-
bilityanddegenerationofeitherSMNinspinalmuscularatrophy
(SMA) (Ro ¨sler et al., 2000; Beckman et al., 2001; Brown and
Robberecht, 2001; Bruijn et al., 2004; Stewart et al., 2006; Turner
and Talbot, 2008) or CSMN in hereditary spastic paraplegia
(HSP) and sporadic primary lateral sclerosis (PLS) (Fink, 2002,
2006; Rainier et al., 2003). ALS is a “system degeneration disor-
der,” with progressive degeneration of both CSMN and SMN,
withincreasingevidenceforinvolvementofbroadercorticalneu-
ronal and widely distributed nonneuronal pathology (Lomen-
Hoerth et al., 2003; Strong, 2008), including astrogliosis and
activated microglia in the neocortex of select ALS patients (Gra-
ham et al., 2004; Brown, 2005; Stewart et al., 2006).
Both inherited (familial) and sporadic forms of ALS show
similar cardinal features: clinical course and neuropathology
(Bendotti and Carrì, 2004; Boille ´e and Cleveland, 2004; Bruijn et
al., 2004; Pasinelli and Brown, 2006). Thus, transgenic mouse
models generated based on genetics of even relatively rare inher-
ited forms of ALS offer important tools with which to investigate
both sporadic and familial ALS, if patient pathology is faithfully
reflected (Gurney, 1997, 2000). Toxic “gain of function” muta-
tion in the superoxide dismutase-1 (SOD1) gene, linked to 10–
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an ALS-like SMN degeneration phenotype in hSOD1
G93A trans-
genic mice (Gurney et al., 1994; Tu et al., 1996; Gurney, 1997;
Kunst et al., 1997; Beckman et al., 2001; Wong et al., 2002; Ben-
dotti and Carrì, 2004; Wengenack et al., 2004; Hegedus et al.,
2007). In contrast to considerable investigation of SMN in
hSOD1
G93A and other models (Chiu et al., 1995), much less is
known about cortical components [degeneration of CSMN and
subcerebral projection neurons (SCPN) that constitute cogni-
tive, association, and integrative sensory circuitry (Zang and
Cheema, 2002; Lobsiger et al., 2005; Yamanaka et al., 2006), and
whether widely distributed nonneuronal pathology observed in
select ALS patients is recapitulated in hSOD1
G93A mice].
ReportsonhSOD1
G93Amicehavesuggestedthattheirneuro-
pathologyisrestrictedmainlytospinalandbulbarmotorneuron
degeneration, but not in cortex (Wong et al., 2002; Ralph et
al., 2005; Niessen et al., 2006), potentially suggesting that
hSOD1
G93AmicedonotrepresentthecompletehumanALSphe-
notype. The lack of data on CSMN is perhaps not surprising,
since only 6000 CSMN exist per hemisphere in mice, inter-
mixed with millions of other cortical pyramidal neurons in the
sameregionandlayerVofmotorcortex.Identificationofspecific
degenerationofCSMNandrelatedSCPNisenabledwithrecently
identified molecular markers and knowledge about CSMN/
SCPN developmental relationship (Gurney, 2000; Arlotta et al.,
2005;Molyneauxetal.,2005,2007,2009;Tomassyetal.,2010).A
fewstudiesreportcorticospinaltractinvolvementinhSOD1
G93A
mice(ZangandCheema,2002;Lobsigeretal.,2005;Yamanakaet
al., 2006), although complexities noted above limited analyses.
One study, using retrograde labeling from spinal cord at postna-
tal day 60 (P60), reported CSMN loss (Zang and Cheema, 2002),
although it was difficult to assess the following: (1) whether ob-
served reduction in retrogradely labeled neurons was due to ab-
normal retrograde axonal transport or true neuronal loss; (2)
whether specific CSMN degeneration or broader cortical degen-
eration occurs; (3) whether observed abnormalities develop be-
fore P60; or (4) whether broader populations of SCPN/other
neurons are affected.
To provide a foundation for increasingly detailed investiga-
tion of CSMN/SCPN biology in ALS and for critical analysis of
cellular and molecular mechanisms of shared biology between
CSMN/SCPN and SMN components of motor neuron circuitry,
we investigated whether distinct and specific degeneration of
CSMN (with additional but not yet clarified non-CSMN cortical
degeneration), as observed in ALS patients (Ro ¨sler et al., 2000;
Zanette et al., 2002; Stewart et al., 2006), is faithfully reproduced
in hSOD1
G93A mice. Our results allow increasingly detailed cel-
lular and molecular investigation of the biology of CSMN and
broader molecularly and developmentally related populations of
SCPN in hSOD1
G93A mice. Elucidating this CSMN/SCPN biol-
ogymightpotentiallycontributetowarddevelopmentofpreven-
tive and/or reparative therapeutics for ALS and related CSMN/
SCPN degenerative diseases.
MaterialsandMethods
Mice. Male and female wild-type (WT), hemizygous transgenic mice
overexpressingthewild-typehumanSOD1gene(hSOD1
WT),andhemi-
zygous transgenic mice expressing the SOD1 gene containing the G93A
mutation in (hSOD1
G93A) were used (Fig. 1A). All mouse strains are on
the C57BL/6 background, and the range of gene copy number, deter-
mined before surgery, was the same in hSOD1
G93A and hSOD1
WT mice
(30  2). Thy1-YFP-hSOD1
G93A and Thy1-YFP-hSOD1
WT mice were
generated by breeding Thy1-YFP mice [gift from J. Sanes, Harvard Uni-
versity, Boston, MA (Bareyre et al., 2005)] and hemizygous hSOD1
G93A
or hSOD1
WT transgenic mice, respectively. Thy1-YFP;WT mice were
used as controls. All mouse studies were approved by the Massachusetts
General Hospital Institutional Animal Care and Use Committee and
performed in accordance with institutional, federal, and National Insti-
tutes of Health guidelines.
CSMN labeling and tissue collection. CSMN were retrogradely labeled
via stereotactic FluoroGold injections (2% FG, 250 nl/mouse) into the
cervical region (C4–C6) of the corticospinal tract within the dorsal fu-
niculus of the spinal cord at distinct, phenotypically distinguishable
times defined previously (Gurney et al., 1994; Tu et al., 1996; Hall et al.,
1998;ClevelandandRothstein,2001;Wengenacketal.,2004;Hegeduset
al., 2007) as P20, “early”; P50, “symptomatic”; and P110, “end stage.” In
a subset of experiments, mice injected at P50 were perfused at P120 to
distinguish between genuine CSMN degeneration and potential appear-
ance of reduced FG labeling due to defects in axonal transport (Fig. 1A,
“#”).TendaysafterFluoroGoldinjection,miceweredeeplyanesthetized
and perfused with cold 0.1 M PBS supplemented with heparin, followed
bycold4%paraformaldehyde(PFA)in0.1 MPBS.Tofurtherinvestigate
whether degeneration of other neocortical projection neurons with
equivalentlylongaxons[mostnotably,interhemisphericcallosalprojec-
tion neurons (CPN)] occurs, in a subset of experiments dual CPN and
CSMN retrograde labeling was performed in hSOD1
G93A and WT mice
at P30, and mice were perfused at P120. CPN were retrogradely labeled
via stereotactic injection of green fluorescent microspheres into con-
tralateral cortex (250 nl/mouse), and CSMN were retrogradely labeled
viastereotacticinjectionofredfluorescentmicrospheres(250nl/mouse)
into the cervical region (C4–C6) of the corticospinal tract within the
dorsal funiculus of the spinal cord. Brains were postfixed in 4% PFA
overnight, and 40 m thick coronal sections were cut on a Leica VT
1000S vibrating microtome.
Immunocytochemistry, Nissl staining, and in situ hybridization. All im-
munocytochemical procedures were performed on every twelfth tissue
sectionof40-m-thickcoronalsections.Thefollowingprimaryantibod-
ies were used: FG (1:500, Millipore Bioscience Research Reagents),
CTIP2 (1:200, Calbiochem), LMO4 (1:200, Santa Cruz Biotechnology),
cleaved caspase 3 (1:250, Cell Signaling), parvalbumin (PV; 1:500,
Sigma),neuropeptideY(NPY;1:500,Immunostar),GFAP(1:200,Santa
Cruz Biotechnology), CD68 (1:100, Millipore Bioscience Research Re-
agents), and FoxP2 (1:250, Abcam). Appropriate secondary fluorescent
antibodies (1:500, Alexa 488 and 546, Invitrogen) were applied in block-
ing solution at room temperature, in the dark, for 2–4 h. CTIP2 and
LMO4 immunocytochemical analysis were enhanced by increased pri-
mary antibody incubation (2 d) at 4°C, and 1:200 dilution was used for
secondary fluorescent antibodies at 4°C overnight. Nuclear counterstain
(ToPro; 1:5000 in 0.1 M PBS) was used to investigate nuclear pyknosis.
Nissl staining was performed on every twelfth comparable section (40
mthick,coronal)isolatedfromWT,hSOD1
WT,andhSOD1
G93Amice.
Cry-mu, Igfbp4, Cux2, Fezf2, and PlexinD1 probes were prepared, and in
situhybridizationanalysiswasperformedaspreviouslydescribed(Moly-
neaux et al., 2005, 2009).
Imaging,quantification,andstatisticalanalysis.Sectionsweremounted
on slides and analyzed using a Nikon E1000 fluorescence microscope
equipped with an X-Cite 120 illuminator (EXF0), and images were ac-
quired using a cooled charge-coupled device digital camera (Q Imaging
Retiga EX). Confocal images were collected using a Bio-Rad Radiance
2100 Rainbow laser scanning confocal microscope based on a Nikon
E800 microscope.
Quantitative analyses were performed on three matched rostrocaudal
sectionsseparatedby480meach[every12sections;40msection
thickness(supplementalFig.1,availableatwww.jneurosci.orgassupple-
mental material)]. Three adjacent fields defined by the 20 objective
encompass the mediolateral extent of retrogradely labeled CSMN; the
same systematically located fields were used for analysis in all mice.
CSMN were counted only if their soma and apical dendrite were both
visualized in the same thick 40 m section. Representative sections and
the locations of the three systematically located fields used for quantifi-
cationofCSMNnumberandsomadiameterinWT(P30,n5;P60,n
5; P120, n  5), hSOD1
WT (P30, n  5; P60, n  5; P120, n  5), and
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G93A (P30, n  5; P60, n  5; P120, n  8) mice are shown in
supplemental Figure 1 (available at www.jneurosci.org as supplemental
material).Foreachmouse,atotalofninefieldswerecounted(threefields
in each of three sections), and numbers were averaged. All statistical
analyses were performed with INSTAT software (version 3.0a; Graph-
pad); parametric and nonparametric multiple-comparison tests, such as
Bonferroni and Tukey tests, were used where appropriate, with a mini-
mum significance level set at p  0.05.
Quantification of interneuron number was performed based on ex-
pression of PV and NPY. Three comparable 40 m coronal sections that
span the motor cortex (supplemental Fig. 1, available at www.jneurosci.
org as supplemental material) from WT (P120, n  2) and hSOD1
G93A
(P120, n  3) mice were analyzed. To perform unbiased and inclusive
quantitative analysis, the cortex was divided into three equal sectors,
mediolaterally/radially defined by equal 30° arcs. All neurons with both
full cell bodies and immunopositivity for PV and NPY were counted in
Figure1. CSMNprogressivelydegenerateinhSOD1
G93Amice.A,Schematicdiagramofexperimentaldesign.WT,hSOD1
G93A,andhSOD1
WTmicewereretrogradelylabeledbyFluoroGold(FG)
injectionstobeanalyzedatP30(presymptomatic),P60(symptomatic),andP120(end-stage).Inasubsetofexperiments,CSMNwereretrogradelylabeledatP50andanalyzedatP120(#).B,
RetrogradelylabeledCSMNresideinlayerVofthemotorcortexanddisplaydistinctCSMNmorphology(inset).C,D,ConfocalanalysisrevealscolocalizationoftheCSMN/SCPN-specific(within
neocortex)transcriptionfactorCTIP2(C)andexclusionoftheCSMN-excludedtranscriptionfactorLMO4(D)inretrogradelylabeledCSMN.E,F,Comparableandrepresentativecoronalsectionsofthe
motor cortex from WT, hSOD1
WT, and hSOD1
G93A mice at P30 (E) and at P120 (F). The boxed areas are enlarged in the adjacent panels to show retrogradely labeled CSMN. G, Bar graph
representationofaverageCSMNsomadiameterinWT,hSOD1
WT,andhSOD1
G93AmiceatP30,P60,andP120.H,BargraphrepresentationoftheaveragenumberofCSMNper20fieldinWT,
hSOD1
WT,andhSOD1
G93AmiceatP30,P60,andP120.CSMNthatwereretrogradelylabeledatP50andanalyzedatP120arelabeledwith“#”.Scalebars:C,40m;D,50m.Dataarepresented
asmeanSEM*p0.05;**p0.0001;G,H,Bonferronitestprecededbytwo-wayANOVA.
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G93AMiceeach sector. All counts were performed “blinded” to the genotype of the
sample by two independent observers. Interobserver variability was ex-
tremely low, with 3% variation between independent measurements.
To investigate the corticospinal tracts of Thy1-YFP;hSOD1
G93A mice
(P30, n  2; P60, n  3; P120, n  4) and Thy1-YFP;hSOD1
WT mice
(P30, n  3; P60, n  3; P120, n  3), spinal cords were isolated intact,
and the cervical and lumbar segments of the spinal cords were sectioned
axially (50 m section thickness), whereas the thoracic segment was
sectioned sagittally (150 m section thickness). All thoracic segments
containingaxonsweremountedonslides,andimagesofallsectionsthat
contained corticospinal tract axons were digitally collapsed to obtain a
two-dimensional image to indicate the whole extent of the corticospinal
tract. Representative axial sections of cervical and lumbar spinal cord
were also imaged.
Results
CSMNprogressivelydegenerateinhSOD1
G93A mice
Weusedacombinationofanatomicalandmolecularapproaches
to identify, quantify, and assess potential vulnerability and pro-
gressive degeneration of CSMN. We retrogradely labeled
CSMN by FG injection into the corticospinal tract within the
dorsalfuniculusoftheC4–C6regionofthespinalcord(Fig.1A).
CSMN were retrogradely labeled at P20 for analysis at P30 (pre-
symptomatic), at P50 for analysis at P60 (symptomatic), and at
P100 for analysis at P120 (end-stage). In a subset of experiments
designed to distinguish between genuine CSMN degeneration
andpotentialappearanceofreducedFGlabelingduetodefectsin
axonal transport, CSMN were retrogradely labeled at P50 and
analyzed at P120 (Fig. 1A, “#”). P30, P60, and P120 times were
chosen based on published and well established stages of disease
progressionwithrespecttobothobservedbehavioralphenotypic
changes and spinal motor neuron degeneration in hSOD1
G93A
mice (Gurney et al., 1994; Hegedus et al., 2007). CSMN identity
was established unequivocally by retrograde labeling from axon
projectionsinthespinalcord,andverifiedbasedon(1)neuronal
locationintheprimarymotorcortex,(2)distinctivelargeCSMN
morphology, and (3) expression of multiple recently identified
positive and negative molecular markers that are either specifi-
callyexpressedorexcludedbyCSMN(andrelatedSCPNinsome
cases). Retrogradely labeled CSMN were confirmed to reside in
layer V of the motor cortex and displayed distinct somatoden-
dritic morphology of CSMN: they have a large pyramidal cell
body and a long apical dendrite (Fig. 1B). Retrogradely labeled
neurons expressed CTIP2 (Arlotta et al., 2005), a CSMN-specific
(and cortico-brainstem; together, subcerebral-specific) tran-
scriptionfactorinlayerV(n150,100%)(Fig.1C),anddidnot
express LMO4, a transcription factor excluded from CSMN in
layer V (n  120, 0%) (Fig. 1D), confirming their CSMN iden-
tity.AlthoughbothCTIP2andLMO4expressionlevelsarehigh-
est during development, and reduce with age, they remain
specific and detectable (Fig. 1C,D) (see Materials and Methods).
Homogeneity in the background of the WT, hSOD1
WT, and
hSOD1
G93A mice, and the consistent copy number of transgenic
gene expression (30  2) in hSOD1
WT and hSOD1
G93A mice
resulted in highly reproducible timing of disease onset and pro-
gression, enabling detailed and reproducible qualitative and
quantitative analysis of CSMN degeneration at specific times
during disease progression.
Qualitative analysis of retrogradely labeled CSMN in layer V
of motor cortex in P30, P60, and P120 WT, hSOD1
WT, and
hSOD1
G93A mice reveals dramatic CSMN vulnerability and
marked degeneration in P120 hSOD1
G93A mice compared with
WT and hSOD1
WT controls, present but more subtle at P30 and
P60 (Fig. 1E–H). Quantitative analysis of CSMN soma diameter
and neuron number at P30, P60, and P120 indicates progressive
degenerationofCSMNonlyinhSOD1
G93Amice(Fig.1G,H;sup-
plemental Fig. 1, available at www.jneurosci.org as supplemental
material). CSMN soma diameter in hSOD1
G93A mice signifi-
cantly decreases, even during the “presymptomatic” stage (P30),
and this decrease becomes even more striking with disease pro-
gression(Fig.1G)(142matP30;102matP60;72m
atP120).Incontrast,neitherWTCSMN(192matP30;20
2 m at P60; 20  2 m at P120) nor hSOD1
WT CSMN (18  2
matP30;193matP60;212matP120)(supplemental
Fig. 1, available at www.jneurosci.org as supplemental material)
show any reduction in soma diameter.
QuantitativeanalysisofthenumberofCSMNinmotorcortex
indicates a progressive and dramatic degeneration of CSMN in
hSOD1
G93A mice beginning by P30 (Fig. 1H) (13  1 per 20
fieldatP30,n5mice;101atP60,n6mice;52atP120,
n  8 mice; 6  1 at P120, injected at P50, n  3 mice) (supple-
mental Fig. 1, available at www.jneurosci.org as supplemental
material). In contrast, CSMN of neither WT (15  1 at P30, n 
5mice;142atP60,n5mice;162atP120,n6mice)nor
hSOD1
WT mice (16  1 at P30, n  4 mice; 15  2 at P60, n  5
mice; 14  1 at P120, n  5 mice) demonstrate neuronal degen-
eration. At P120, hSOD1
G93A mice show identical numbers of
retrogradely labeled CSMN, regardless of the time of retrograde
labeling (5  2 at P120, injected at P100, n  8 mice; 6  1a t
P120, injected at P50, n  3 mice), strongly indicating that
CSMN undergo genuine somatic degeneration, and that the re-
duced number of retrogradely labeled CSMN is not due to con-
founding variables related to retrograde transport. In contrast,
rubrospinalneurons,locatedintherednucleus,andprojectingto
the cervical spinal cord (and thus also retrogradely labeled from
thecervicalspinalcordFGinjections)arenormalinnumberand
morphology in hSOD1
G93A mice (as well as in hSOD1
WT and
WT mice) at all ages including P120, reinforcing that degenera-
tion is specific to CSMN in motor cortex in hSOD1
G93A mice
(supplemental Fig. 2, available at www.jneurosci.org as supple-
mental material).
CSMNdegenerationoccursvia apoptosis
InvestigationofCSMNdeathatallthreestagesofdiseaseprogres-
sion, using Nissl staining, analysis for nuclear pyknosis, and
cleavedcaspase-3(CC-3)expression,revealsthatCSMNdeathis
apoptotic,andstartsbyP30inhSOD1
G93Amice(Fig.2).Nuclear
pyknosisisanearlysignofapoptoticcelldeath(deRiveroVaccari
et al., 2006), and CC-3 expression is detected in cells undergoing
active apoptosis, although the time it takes CC-3-positive neu-
rons to ultimately die is reported to take substantially longer in
vivo than in vitro (Yang et al., 1998; Arai et al., 2005). Progressive
apoptosis in hSOD1
G93A spinal motor neurons has been docu-
mentedpreviously(Lietal.,2000;Przedborski,2004;Wengenack
et al., 2004), but CSMN were not investigated in detail. Here, all
three analyses (Nissl, nuclear pyknosis, CC-3) reveal a wave of
apoptoticCSMNdeaththatstartsbyP30inhSOD1
G93Amice.In
strikingcontrast,WTandhSOD1
WTCSMNdonotdemonstrate
neuronal death by any of these three modes of analysis at any
stageinvestigated.AtP30,apoptosisisvisiblebynuclearpyknosis
(Fig. 2A) (40  5% of hSOD1
G93A CSMN, n  290; 1  1% of
WT CSMN, n  271; 3  1% hSOD1
WT CSMN, n  264) (Fig.
2A,D) and reduced soma size (Fig. 1G), and CC-3 expression is
detectedinsomeCSMNinhSOD1
G93Amice(21%,n148),
but not in WT or hSOD1
WT. To further investigate whether nu-
clear pyknosis, and thus neuronal degeneration, might begin
even earlier than P30, we quantified nuclear pyknosis of CTIP2-
O ¨zdinleretal.•CSMN/SCPNDegenerationinhSOD1
G93AMice J.Neurosci.,March16,2011 • 31(11):4166–4177 • 4169positive CSMN in layer V of motor cortex at P5, P10, and P15
compared with WT control CSMN at these same ages. These
analyses reveal that 0% of WT CSMN display pyknotic nuclei at
anyoftheseearlyages(P5,n105;P10,n101;P15,n110),
whereas 2% of P5 hSOD1
G93A CSMN display pyknosis, n  114;
increasing to 4  1% at P10, n  147; and to 7  1% at P15, n 
112.AtP60,thepercentagesofCSMNwithpyknoticnuclei(64
3%,n243)orexpressingCC-3(92%,n140)aresubstan-
tially increased (Fig. 2B,D,E). At P120, CSMN degeneration in
hSOD1
G93A mice is even more dramatic, with 7  2% of CSMN
expressing CC-3, 61  3% with pyknotic nuclei, and near ab-
sence of large pyramidal neurons in layer V of motor cortex by
Nisslstaining(Fig.2C).ItislikelythatCSMNdetectedateachage
wouldincludeCSMN(1)alreadycommittedtodieviaapoptosis,
(2)alreadydysfunctionalandintheprocessofcelldeath,and(3)
dead but not yet cleared from the tissue. These data suggest that
many retrogradely labeled somata of CSMN detected in the cor-
texatP30,P60,and/orP120arealreadylessviable(likelyalready
undergoingdegeneration),buttheyareeithernotyetdeadornot
yet cleared from the tissue. Together, these results indicate by
multiple independent criteria that progressive CSMN degenera-
tion occurs in hSOD1
G93A mice, beginning early during the clas-
Figure2. CSMNdeathoccursviaapoptosis.A,AtP30,hSOD1
WTmicedisplayhealthyCSMNnuclei(i–iv),whileapoptosisisvisiblebynuclearpyknosisinhSOD1
G93ACSMN(i’–iv’,
arrows).Theboxedareas(i–iv,i’–iv’)inthelow-magnificationimagesareenlargedtotheright.B,AtP60,CC-3expressionwasincreasedinmanyhSOD1
G93ACSMN,butisnotdetected
inhSOD1
WTCSMN.C,AtP120,Nisslstainanalysisofmotorcortex,andlayerVinparticular,revealsthenormalcomplementoflargepyramidalneuronsinlayerVofhSOD1
WTmotorcortex
(i, ii)butastrikingreductioninhSOD1
G93Amotorcortex(i’, ii’).Theboxedareas(i–ii’)inthelow-magnificationimagesareenlargedtotheright.D,Bargraphrepresentationofthe
percentageofCSMNwithpyknoticnucleiatP30,P60,andP120inWT,hSOD1
WT,andhSOD1
G93Amice.E,BargraphrepresentationofthepercentageofCSMNexpressingCC-3,atP30,
P60,andP120inWT,hSOD1
WT,andhSOD1
G93Amice.
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WTand
hSOD1
G93AcortexatP120.Theboxedareas(i–iv)inthelow-magnificationimagesareenlargedtotheright;romannumeralsindicatethelayersofmotorcortex.Fezf2(A)isexpressedathighlevelsinlayerVof
motorcortex(i)andnonmotorareas(iii)onlyinhSOD1
WTmice.Fezf2expressionisdramaticallyreducedinthemotorcortex(CSMN)(ii)andinthenonmotorareasofthecortex(SCPN)(Figurelegendcontinues.)
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Broaderdegenerationofdevelopmentallyrelatednonmotor
subcerebralprojectionneuronsoccursinhSOD1
G93Amice
To further investigate whether neocortical neuronal degenera-
tion is specific to CSMN, or might involve other populations of
corticalprojectionneuronsand/orinterneurons,weinvestigated
the neuronal subtype identity and specificity of degeneration,
using laminar and neuron type-specific molecular markers. We
used a combination of immunocytochemical and in situ hybrid-
ization analyses in hSOD1
G93A and hSOD1
WT mice at P120. The
resultsindicatethatneuronaldegenerationextendsspecificallyto
the developmentally related populations of motor and nonmo-
tor, associative subcerebral projection neurons (SCPN), which
includeCSMNinthemotorcortex.Neuronsinotherlayersofthe
neocortex, and other neuron populations in layer V, are not
affected.
Each molecular marker analyzed, both for CSMN/SCPN and
for alternate neuron subtypes and lamina, confirms the spec-
ificity of CSMN/SCPN degeneration in the motor cortex of
hSOD1
G93A mice. Fezf2, a transcription factor required for
CSMN/SCPN specification and development, and expressed at
high levels in CSMN/SCPN throughout life (Molyneaux et al.,
2005; Molyneaux et al., 2007), has normal expression in
hSOD1
WTmiceatP120(Fig.3A).Incontrast,Fezf2expressionin
motor cortex of hSOD1
G93A mice indicates dramatic loss of
CSMN at P120 (Fig. 3Ai,ii). Interestingly, analysis of Fezf2 ex-
pression in nonmotor areas of neocortex indicate additional in-
volvement, but less striking loss, of the broader population of
SCPN (Fig. 3Aiii,iv), which contribute to nonmotor cognitive,
association, and integrative sensory systems in the cortex. Cry-
mu, which is expressed at high levels by CSMN during develop-
ment, and at very low levels by a subset of corticofugal neurons
located in layer VI (Molyneaux et al., 2005; Molyneaux et al.,
2007), displays normal expression in hSOD1
WT mice at P120
(Fig. 3Bi). In striking contrast, cry-mu expression confirms dra-
matic loss of CSMN in motor cortex in hSOD1
G93A mice (Fig.
3Bii). With regard to non-CSMN/SCPN populations, PlexinD1
(Fig. 3C) and Cux2 (Fig. 3D), both expressed in neuron popula-
tions in superficial layers of the neocortex during development
through adulthood (Molyneaux et al., 2007), do not indicate any
difference in superficial layer neuron populations in hSOD1
G93A
versus hSOD1
WT mice. To further differentiate true CSMN/
SCPN neuronal loss from simple gene dysregulation, Igfbp4, ex-
pressedathighlevelsbyCSMNduringdevelopment,andatlower
levels in layer II/III and layer VI neurons in the cortex (Moly-
neaux et al., 2007), displays normal expression in all populations
in hSOD1
WT mice at P120 (Fig. 3E). In contrast, in hSOD1
G93A
mice,Igfbp4expressionissharplyreducedinlayerV(confirming
CSMN/SCPN loss), while its expression is not affected in other
neuron populations located in neocortical layers II/III and VI
(Fig. 3E), further reinforcing the specificity of CSMN/SCPN de-
generation in layer V of motor cortex. To even further consider
whether neuronal degeneration is specific to CSMN/SCPN
amongthebroadercorticofugalpopulations(including,e.g.,cor-
ticothalamic neurons), analysis of deepest layer VI of cortex for
FoxP2 expression does not indicate any difference between
hSOD1
G93A and hSOD1
WT mice (Fig. 3F). Similarly, LMO4, a
transcription factor expressed by callosal projection neurons
(inter-hemispheric, non-CSMN), interneurons, and other pop-
ulations in layer V, but excluded from CSMN in layer V of the
cortex(Arlottaetal.,2005;Molyneauxetal.,2005),isunchanged
between hSOD1
G93A and hSOD1
WT mice (Fig. 3Gi,ii). In addi-
tion, dual retrograde labeling of CPN and CSMN at P30 in
hSOD1
G93A and WT mice with perfusion at P120 indicates 1) no
loss of CPN in hSOD1
G93A mice, 2) striking CSMN/SCPN-
specific loss in hSOD1
G93A mice (again, labeled early to exclude
retrograde transport as a confounding variable), 3) specificity of
CSMN degeneration in motor cortex of hSOD1
G93A mice (sup-
plemental Fig. 3, available at www.jneurosci.org as supplemental
material).
InterneuronsarenotsimilarlyaffectedinhSOD1
G93A mice
To investigate whether vulnerability and degeneration is re-
stricted to CSMN/SCPN in the cortex of hSOD1
G93A mice, or
whether nonprojection neuron populations (interneurons) are
affected, we examined a broad variety of interneurons based on
the interneuron molecular markers parvalbumin and neuropep-
tide Y (NPY) in both hSOD1
G93A (n  3) and WT (n  2) mice
during the end-stage of disease progression. The results indicate
thatcorticalinterneuronpopulationsarenotapparentlyaffected
in hSOD1
G93A mice (Fig. 4). The number of parvalbumin-
expressing interneurons does not differ substantially or signifi-
cantly between hSOD1
G93A and WT mice, in any of the three
mediolateralregions(Fig.4A–C).Further,cellularmorphologies
ofparvalbumin-positivecorticalinterneuronsappearunchanged
between WT and hSOD1
G93A mice, without suggestion of neu-
ronaldegeneration(Fig.4D,E).Similarresultswereobtainedfor
NPY-expressing interneurons (data not shown). A prior report
suggested the possibility of interneuron degeneration in the cor-
tex based on reduced cortical inhibition in ALS patients (Zi-
emannetal.,1997),butouranalysisinhSOD1
G93Amicedoesnot
identify interneuron loss in these model mice. One recent study
suggested increased cortical interneuron numbers in ALS mice,
based on immunocytochemical analysis and applications of
modeling (Minciacchi et al., 2009), but our results using broad
mediolateral and rostrocaudal analysis do not identify such an
increase. While it still remains possible that slight differences
between the transgenic mice exist in localized areas, potentially
secondarytodegenerationofinterneurons’CSMN/SCPNsynap-
tic partners, we find no significant difference in interneurons
more broadly between WT and hSOD1
G93A mouse neocortex.
Astrogliosisandmicrogliosisarepresentlateduring
CSMN/SCPN degeneration
Activatedastrocyteshavebeenimplicatedindiseasepathogenesis
in ALS and have been detected both in ALS patient brains and
spinal cords, and in spinal cords of hSOD1
G93A mice. To investi-
gate whether astrogliosis (and, potentially, microglial activation)
occursinhSOD1
G93Amouseneocortex,andwhetherastrogliosis
4
(Figurelegendcontinued.)( iv)inhSOD1
G93Amice.Cry-mu(B)isexpressedathighlevelsin
CSMNinhSOD1
WTmice(i),andCry-muexpressionisdramaticallyreducedinhSOD1
G93Amice
(ii).PlexinD1(C)andCux2(D),bothexpressedinneuronpopulationsinsuperficiallayersofthe
neocortex,shownodifferencebetweenhSOD1
WTandhSOD1
G93Amice.Igfbp4(E)isexpressed
athighlevelsbyCSMNandatlowerlevelsinlayerII/IIIandVIneuronsinthecortex;hSOD1
WT
mice display a normal complement of CSMN. In contrast, hSOD1
G93A mice have many fewer
Igfbp4-expressingneuronsinlayerV,whileotherneuronpopulationsarenotaffected,further
confirmingthespecificityofCSMNdegeneration.F,FoxP2,expressedinthedeepestlayerVIof
cortex,isunchangedbetweenhSOD1
WTandhSOD1
G93Amice.G,LMO4expression,normally
expressedbylayerVcallosalprojectionneurons,interneurons,andotherpopulations,butex-
cludedfromCSMNinlayerV,isunchangedbetweenhSOD1
WTandhSOD1
G93AmiceatP120(i,
ii), reinforcing the specificity of CSMN degeneration in layer V of motor cortex in hSOD1
G93A
mice.
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sessed the presence of activated astrocytes and/or microglia in
hSOD1
G93A (P30, n  3; P60, n  3; P120, n  4) and in
hSOD1
WT(P30,n2;P60,n2;P120,n3)miceusingGFAP
and CD68 immunocytochemical analysis, respectively. We
find that astrogliosis and microgliosis occur specifically in
hSOD1
G93Amice(Fig.5A–I,M)andnotinhSOD1
WTmice(Fig.
5J–L). It occurs mainly at late stages of disease progression in
hSOD1
G93A mice (Fig. 5G–I) and is not restricted to motor cor-
tex (supplemental Fig. 4, available at www.jneurosci.org as sup-
plemental material). These results suggest that CSMN/SCMN
vulnerabilityanddegenerationisinitiatedbeforeastrogliosisand
microgliosis in the neocortex of hSOD1
G93A mice.
ThecorticospinaltractdegeneratesinhSOD1
G93A mice
Toinvestigatethetimecourseofcorticospinaltract(CST)degen-
erationinhSOD1
G93Amicethatisthepredictedaccompaniment
of the CSMN degeneration we identified in these mice, we ap-
plied genetic CST labeling using hSOD1
G93A, hSOD1
WT, and
WT mice crossed with cortical-specific Thy1-YFP mice (Bareyre
etal.,2005).Inthesemice,multiplepopulationsofcorticalpyra-
midal neurons express yellow fluorescent protein (YFP), while
only CST axons are labeled in the spinal cord. As reflected by the
“lateral sclerosis” component of its original pathologically de-
scriptivename(“sclerosis”ofthe“lateral”—main—corticospinal
tractinprimates),CSTdegenerationiscentraltoALS,asaneasily
visible component of the degeneration of CSMN, whose axons
form the CST. Mice with cortical specific Thy1-YFP neuron la-
beling were used to generate Thy1-YFP;hSOD1
WT and Thy1-
YFP;hSOD1
G93A mice by serial breeding (see Materials and
Methods) (Fig. 6B). Results from Thy1-YFP;hSOD1
G93A (P30,
n  2; P60, n  3; P120, n  3) (Fig. 6A,B) and Thy1-YFP;
hSOD1
WT mice (P30, n  2; P60, n  4; P120, n  5) (Fig. 6B)
indicate that corticospinal tract degeneration is specific to Thy1-
YFP;hSOD1
G93A mice. Degeneration is most dramatic between
P60andP120(Fig.6D–F).CSTinnervationofthelumbarspinal
cord is essentially absent in Thy1-YFP;hSOD1
G93A mice by the
latestagesofdiseaseprogression(Fig.6Eiii),andthereissubstan-
tiallossofthecervicalcorticospinaltract(Fig.6Ei).Theseresults
indicatethatCSMNsomaldegenerationthatoccursquiteearlyis
followed by profound corticospinal tract degeneration by late
stages in hSOD1
G93A mice.
Discussion
Together, using a combination of anatomic, cellular, transgenic
labeling, and newly available neuronal subtype-specific molecu-
lar analyses of both laminar and neuronal subtype identity, these
results demonstrate that early and neuron type-specific CSMN/
SCPN (both motor and nonmotor) neuronal degeneration is
faithfully recapitulated in hSOD1
G93A transgenic ALS mice.
Other neuron populations in other layers of the neocortex,
other neuron populations within layer V, and interspersed
cortical interneurons do not undergo such degeneration.
Thus, hSOD1
G93A mice develop specific CSMN/SCPN degener-
ation that mirrors the cortical pathology found in human ALS,
and nonmotor SCPN degeneration might explain some or much
of the nonmotor cortical pathology identified in ALS. This neu-
rontype-specificdegenerationinhSOD1
G93Amicebeginsexcep-
tionally early, in the presymptomatic stage, coincident with the
earliest degeneration of spinal motor neurons (Gurney et al.,
1994; Tu et al., 1996; Hall et al., 1998; Cleveland and Rothstein,
2001; Bruijn et al., 2004; Wengenack et al., 2004; Hegedus et al.,
2007). These results are consistent with longstanding clinical ev-
idence and more recent human magnetic resonance imaging
Figure4. CorticalinterneuronpopulationsdonotsimilarlydegenerateinhSOD1
G93Amice.A–C,PV-positiveinterneuronswerequantifiedinhSOD1
G93AandWTmousecortexatP120.Thecortex
wasdividedintothreeequalsectorsandparvalbumin-positiveneuronscountedineachsector.A,PVimmunocytochemistryincoronalsectionsoftworepresentativeexamplesofhSOD1
G93Amouse
cortex;onewiththehighestnumberofPV-positiveinterneurons(top)andonewiththelowestnumberofPV-positiveinterneurons(bottom).B,PVimmunocytochemistryinacoronalcorticalsection
ofarepresentativeWTmouse.C,BargraphdisplayingthetotalnumberofPV-positiveneuronsineachsectorofthecorticesfromWTandhSOD1
G93Amice.D,E,Cellularmorphologiesofinterneurons
wereunchangedbetweenhSOD1
G93A(D)andWTmice(E),withoutsuggestionofneuronaldegeneration.
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affected at early stages of ALS (Brown, 2005; Graham et al.,
2004; Stewart et al., 2006). The data reveal early events of
CSMN degeneration by P30, with progressive CSMN degen-
eration occurring via apoptosis. Neocortical neuron degener-
ation is specific to CSMN/SCPN in the cerebral cortex of
hSOD1
G93A mice. In contrast, other cortical neuron popula-
tions do not undergo such degeneration—other cortical pro-
jection neuron populations in other layers of the cortex, other
projection neuron populations within cortical layer V, or in-
terneurons. CSMN undergo true cellular degeneration, not
simply defects in retrograde axonal transport, shown to be
separable issues by multistage retrograde labeling experiments.
CSMN-specific degeneration is accompanied by striking cortico-
spinal tract degeneration later in disease progression, revealed
by transgenic labeling of corticospinal tract axons in Thy1-
YFP;hSOD1
G93A mice. These experiments and findings pro-
vide a foundation for detailed investigation of CSMN/SCPN
Figure5. AstrogliosisandmicrogliosisisobservedinhSOD1
G93Amice.A–I,AstrogliosisinmotorcortexofhSOD1
G93AmiceatP30(A–C),P60(D,E),andP120(G–I).Theboxedareasinthe
low-magnificationimagesareenlargedtotheright.AlthoughprogressiveCSMNdegenerationisobservedinhSOD1
G93AmiceatP30toP60(B,C,E,F)andP120(B,C,E,F,H,I),activatedastrocytes
werefirstdetectedbyGFAPexpressionlater,hereshownatP120(H,I).AstrogliosiswasspecifictohSOD1
G93Amice,andhSOD1
WTmicedonotdisplayactivatedastrocytesatP120(J–L).Similarly,
activatedmicrogliaweredetectedbyCD68expressiononlyinhSOD1
G93Acortex(M)andnotinhSOD1
WTcortex(N)atP120.
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tween CSMN and SMN upper and lower motor neurons,
respectively.
ItisquitenotablethatCSMNdegenerationisaccompaniedby
degeneration of the related broader category of SCPN. Types of
SCPN other than CSMN are molecularly and developmentally
closely related to CSMN, and their coincident degeneration
mightbeinpartresponsibleforthebroadercorticalpathologyin
cognitive, association, and even sensory systems in many ALS
cases. This further links the findings in hSOD1
G93A mice to this
emergingly important biology in humans with ALS. To further
ourunderstandingofCSMN/SCPNdegenerationinhumanALS,
neuron type-specific analysis coupled with cellular and genetic
labeling now enables deeper investigation regarding the cortical
componentofpathologyinhSOD1
G93Amice.Suchinvestigation
can now build on both basic anatomical analysis of the cortex/
corticospinal tract, and on new molecular knowledge about
subtype-specificdifferentiationandmarkers(Arlottaetal.,2005;
Molyneauxetal.,2005,2007,2009;Tomassyetal.,2010).Usinga
combination of anatomical, cellular, transgenic labeling, and
newly available neuronal subtype-specific molecular analyses
to identify, quantify, and assess progressive and neuron type-
specific degeneration of CSMN and related SCPN in
hSOD1
G93A transgenic ALS mice, these experiments closely link
themouseandhumancorticospinalandbroadercorticalbiology
of ALS. These analyses can now be extended by other investiga-
tors to other mammalian models of ALS to more deeply and
rigorously elucidate the extent and mechanisms of cortical pa-
thology.Suchinvestigationswilllikelyalsoelucidatemechanisms
ofCSMN/SCPNdegenerationinotheruppermotorneuronneu-
rodegenerativediseases,suchashereditaryspasticparaplegiaand
primary lateral sclerosis.
CSMN and SMN degenerate independently, but their degen-
eration is potentially mechanistically related. CSMN and SMN
are located at distant locations in the CNS, have very different
developmental histories, and are positioned in distinct but po-
tentially related microenvironments (with related glutamatergic
synapses, transmission, and functions of surrounding astroglia,
and potentially some shared channel properties). However, their
progressiveandspecificdegenerationindicatestherelevanceand
importance of potentially common biology between these upper
and lower motor neurons in ALS.
Sufficient information is developing to begin to elucidate
common and/or unique biology between CSMN and SMN dur-
ing development, and in ALS and related neurodegenerative
diseases. There has been deep and important work on the dif-
ferentiation, development, and maturation of spinal motor neu-
rons (Tanabe and Jessell, 1996; Ericson et al., 1997; Arber et al.,
1999; Briscoe et al., 1999; Pierani et al., 2001; Wichterle et al.,
2002; William et al., 2003; Dasen et al., 2003, 2005; Kania and
Jessell, 2003; Lanuza et al., 2004; Fox et al., 2007; Azim et al.,
2009a,b; Molyneaux et al., 2009). In addition, cellular and mo-
lecular controls over differentiation, development, and matura-
tion of CSMN/SCPN and other populations of neocortical
projection neurons are beginning to emerge (Arlotta et al., 2005;
B.Chenetal.,2005;J.G.Chenetal.,2005;Molyneauxetal.,2005,
2007, 2009; Ozdinler and Macklis, 2006; Joshi et al., 2008; Lai et
al., 2008; Azim et al., 2009a,b; Tomassy et al., 2010). Moreover,
Figure6. ThecorticospinaltractdegeneratesinThy1-YFP;hSOD1
G93Amice.A,BreedingofhSOD1transgenicmicewithThy1-YFPtransgenicmicewasusedtovisualizetheCSTinhSOD1
G93Aand
hSOD1
WTmice.SchematicdrawingofcerebralcortexandspinalcordofThy1-YFPtransgenicmice,inwhichtheCSTisvisualizedbyYFPfluorescenceinthespinalcord.Cervicalandlumbarsegments
ofthespinalcordwereinvestigatedbysingle50-m-thickaxialsections(i,iii).Sagittalsectionswereusedforthethoraciccord;toidentifytheentireextentoftheCSTinthethoracicsegment,all
150-m-thicksagittalsectionscontainingCSTaxonsweredigitallycollapsedintoasingletwo-dimensionalimage(ii).B,Thy1-YFP;hSOD1
G93AandThy1-YFP;hSOD1
WTmice(hemizygousforboth
theThy1-YFPandthehSOD1
G93Agenes)weregeneratedbyserialbreedingThy1-YFPmiceandhSOD1
G93AorhSOD1
WTmice,respectively.Thy1-YFP;WTmicewereusedascontrols.C–E,Insets(Ci,
Di,Ei,Ciii,Diii,Eiii)showhigher-magnificationviewsofthedorsalfuniculi,indicatingCSTaxonsatboththecervical(i)andlumbar(iii)segmentsofthespinalcord.C,AtP120,theCSTdidnotshow
anysignofdegenerationinThy1-YFP;hSOD1
WTmice.TheCSTisnormalinthecervical(i),thoracic(ii),andlumbarspinalcord(iii).D,E,InThy1-YFP;hSOD1
G93Amice,CSTdegenerationismost
dramaticbetweenP60andP120.Thereissubstantiallossofcervical(Di)andthoracic(Dii)CSTaxonsbyP120,andinnervationofthelumbarspinalcordisdrasticallyreducedtoabsentinThy1-YFP;
hSOD1
G93AmiceatP120(Diii).
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in corticospinal motor neuron circuitry in the cerebral cortex of
ALS patients and the progressive cortical pathology with respect
to spinal motor neuron degeneration (Vucic et al., 2008; Siva ´ket
al., 2010; van der Graaff et al., 2010; Mohammadi et al., 2011).
Emerging evidence also indicates the relevance of SOD1 pathol-
ogy in at least some sporadic ALS cases and extends the impor-
tance of understanding SOD1-mediated pathology well beyond
familial ALS (Bosco et al., 2010). These studies, together with
increasing understanding regarding the biology of both upper
andlowermotorneurons,mightcontributetowarddevelopment
of future diagnostic and therapeutic approaches.
Understanding cellular and molecular mechanisms of cell
type-specific degeneration in neurodegenerative diseases is of
major and important interest toward both prevention and ther-
apy.Together,ourinvestigationsestablishandclarifythecentral,
early, specific, and independent involvement of CSMN/SCPN in
hSOD1
G93A mice, and develop neuron type-specific ap-
proaches for analysis of the upper motor neuron component of
neurodegeneration and its potential prevention or therapy in
hSOD1
G93A mice and other rodent models of ALS.
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